Get the Stockscreener App
87.60
1.12%
-0.81
Biontech Se Adr stock is traded at $87.60, with a volume of 373.64K.
It is down -1.12% in the last 24 hours and down -21.16% over the past month.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
See More
Previous Close:
$88.41
Open:
$87.14
24h Volume:
373.64K
Relative Volume:
0.31
Market Cap:
$22.02B
Revenue:
$3.32B
Net Income/Loss:
$-1.26B
P/E Ratio:
-16.75
EPS:
-5.2311
Net Cash Flow:
$289.80M
1W Performance:
-7.84%
1M Performance:
-21.16%
6M Performance:
-12.36%
1Y Performance:
-13.13%
1-Day Range:
$86.33
$87.79
1-Week Range:
$86.33
$93.77
52-Week Range:
$79.52
$124.00
Biontech Se Adr Stock (BNTX) Company Profile
Compare BNTX vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTX
Biontech Se Adr
|
87.62 | 22.22B | 3.32B | -1.26B | 289.80M | -5.2311 |
VRTX
Vertex Pharmaceuticals Inc
|
450.55 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
735.25 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
676.63 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.09 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
142.19 | 31.04B | 606.42M | -1.28B | -997.58M | -6.403 |
Biontech Se Adr Stock (BNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-16-26 | Upgrade | Goldman | Neutral → Buy |
| Jun-05-25 | Reiterated | H.C. Wainwright | Buy |
| May-29-25 | Initiated | Goldman | Neutral |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Jan-10-25 | Initiated | Truist | Buy |
| Dec-11-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Reiterated | BMO Capital Markets | Outperform |
| Nov-19-24 | Initiated | Berenberg | Buy |
| Nov-19-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-08-24 | Upgrade | Goldman | Neutral → Buy |
| Sep-24-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-16-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-07-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-02-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-14-24 | Initiated | Evercore ISI | In-line |
| Feb-23-24 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-24 | Initiated | Oppenheimer | Perform |
| Dec-01-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-16-23 | Downgrade | HSBC Securities | Buy → Hold |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-17-23 | Upgrade | Redburn | Neutral → Buy |
| Dec-15-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-17-22 | Initiated | Cowen | Market Perform |
| Jul-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Dec-16-21 | Initiated | Morgan Stanley | Equal-Weight |
| Nov-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-22-21 | Initiated | Deutsche Bank | Hold |
| Oct-07-21 | Initiated | Jefferies | Hold |
| Aug-11-21 | Upgrade | Bryan Garnier | Neutral → Buy |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-16-21 | Downgrade | Redburn | Neutral → Sell |
| May-18-21 | Initiated | Goldman | Neutral |
| May-11-21 | Downgrade | Bryan Garnier | Buy → Neutral |
| Dec-01-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-03-20 | Resumed | Berenberg | Buy |
| Jul-21-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-30-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-19-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-28-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-09-20 | Initiated | H.C. Wainwright | Neutral |
| Jan-24-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jan-22-20 | Downgrade | UBS | Buy → Neutral |
| Nov-05-19 | Initiated | Wolfe Research | Outperform |
| Nov-04-19 | Initiated | Berenberg | Buy |
| Nov-04-19 | Initiated | BofA/Merrill | Buy |
| Nov-04-19 | Initiated | Canaccord Genuity | Buy |
| Nov-04-19 | Initiated | JP Morgan | Overweight |
| Nov-04-19 | Initiated | SVB Leerink | Outperform |
| Nov-04-19 | Initiated | UBS | Buy |
View All
Biontech Se Adr Stock (BNTX) Latest News
Anaveon appoints Biotech Leader Thaminda Ramanayake as Chief Executive Officer - GlobeNewswire Inc.
BioNTech stock plunges as founders leave. Should you buy the dip in BNTX here? - MSN
AKT I: „ICI VARSOVIE” [c66293] - Fathom Journal
BioNTech's Oncology Pivot Accelerates Amid Leadership Transition and €17B Cash Reserve - AD HOC NEWS
Hudson Bay Capital Management LP Acquires 55,004 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech Stock Forecast | Co-Founders Plan Departure - Capital.com
Groupama Asset Managment Trims Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BNTX Stock Price, Quote & Chart | BIONTECH SE-ADR (NASDAQ:BNTX) - ChartMill
Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
BioNTech a Takeover Target? What's Happening at CHAR Technologies and Steyr Motors? - news.financial
symbol__ Stock Quote Price and Forecast - CNN
125,000 Shares in BioNTech SE Sponsored ADR $BNTX Purchased by Ghisallo Capital Management LLC - MarketBeat
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Dodge & Cox - MarketBeat
BioNTech SE Stock (ISIN: US09075V1026) Faces Pressure After Leadership Exodus and Earnings Miss - AD HOC NEWS
BNP Paribas Financial Markets Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech's Promising Oncology Pipeline Is Now in Late-Stage Development - Morningstar
BioNTech (NASDAQ:BNTX) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Serve Robotics Posts Upbeat Q4 Results, Joins Auna, Acacia Research And Other Big Stocks Moving Higher On Wednesday - Benzinga
BMO cuts BioNTech stock price target on CEO departure plans - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Sold by Capital International Inc. CA - MarketBeat
Form 144 BioNTech SE For: 11 March - Investing.com
BioNTech tumbles over 19% on fourth quarter earnings miss - Investing.com
Oppenheimer maintains BioNTech stock rating amid leadership exit - Investing.com
BioNTech stock price target lowered to $167 by Clear Street - Investing.com
BioNTech Stock Plunges as Founders Leave. Should You Buy the Dip in BNTX Here? - inkl
Truist reiterates Buy on BioNTech stock after revenue guidance - Investing.com
BofA cuts BioNTech stock price target on leadership transition - Investing.com South Africa
Micron and BioNTech among market cap stock movers on Tuesday By Investing.com - Investing.com India
Micron and BioNTech among market cap stock movers on Tuesday - Investing.com
BioNTech (NASDAQ:BNTX) Hits New 1-Year LowHere's What Happened - MarketBeat
BioNTech Q4 Earnings Call Highlights - Yahoo Finance
BioNTech co-founding couple Sahin and Tuereci leaving to create new company - The Globe and Mail
FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
BioNTech founders to establish new mRNA company, step down by year-end - Investing.com
Biontech Se receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
BioNTech earnings loom with revenue dive, pipeline progress in focus - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Acquired by Victory Capital Management Inc. - MarketBeat
BioNTech's Upcoming Financial Report Draws Investor Scrutiny Amid Strategic Pivot () - aktiencheck.de
Is BioNTech SE (BNTX) A Good Stock To Buy Now? - Finviz
BioNTech Expands Infectious Disease Pipeline With New Mpox mRNA Vaccine Trial in Africa - TipRanks
Sobre Bruno Hansmann - eToro
Primecap Management Co. CA Sells 130,700 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Analysts’ Top Healthcare Picks: Ascendis Pharma (ASND), BioNTech SE (BNTX) - The Globe and Mail
BioNTech Escalates mRNA Legal Battle with Moderna Over Next-Gen Vaccine () - aktiencheck.de
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
BioNTech’s New HIV Antibody Trial Adds Depth to BNTX’s Long-Term Pipeline Story - TipRanks
BioNTech SE (BNTX) Rallying on Solid Oncology Strategy - Finviz
BioNTech SE Sponsored ADR $BNTX Shares Sold by CenterBook Partners LP - MarketBeat
BioNTech's Strategic Pivot: Key Catalysts on the 2026 Horizon () - aktiencheck.de
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock? - Finviz
Biontech Se Adr Stock (BNTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.96%
3.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):